381 related articles for article (PubMed ID: 30093325)
1. Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19
Golay J; Martinelli S; Alzani R; Cribioli S; Albanese C; Gotti E; Pasini B; Mazzanti B; Saccardi R; Rambaldi A; Introna M
Cytotherapy; 2018 Aug; 20(8):1077-1088. PubMed ID: 30093325
[TBL] [Abstract][Full Text] [Related]
2. Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines.
Durrieu L; Lemieux W; Dieng MM; Fontaine F; Duval M; Le Deist F; Haddad E
Cytotherapy; 2014 Jun; 16(6):845-56. PubMed ID: 24529554
[TBL] [Abstract][Full Text] [Related]
3. Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines.
Durrieu L; Gregoire-Gauthier J; Dieng MM; Fontaine F; le Deist F; Haddad E
Cytotherapy; 2012 Nov; 14(10):1245-57. PubMed ID: 22974386
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
5. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
[TBL] [Abstract][Full Text] [Related]
6. Augmented CD3(+)CD8(+) and CD3(+)CD56(-) cells in cytokine-induced killer cells cultured with engineered cells for costimulatory enhancement from heavily pretreated patients with solid tumor.
Wang L; Yi Y; Yin D; Zhou Z; Fan J; Ye W; Zhao W
Cytotherapy; 2016 Apr; 18(4):581-9. PubMed ID: 26971686
[TBL] [Abstract][Full Text] [Related]
7. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
8. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.
Malik-Chaudhry HK; Prabhakar K; Ugamraj HS; Boudreau AA; Buelow B; Dang K; Davison LM; Harris KE; Jorgensen B; Ogana H; Pham D; Schellenberger U; Van Schooten W; Buelow R; Iyer S; Trinklein ND; Rangaswamy US
MAbs; 2021; 13(1):1890411. PubMed ID: 33818299
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignancies.
Zhang Z; Wang L; Luo Z; Zhao X; Huang J; Li H; Yang S; Zhao X; Zhang L; Li L; Wang F; Huang L; Zhang Y
Cytotherapy; 2015 Aug; 17(8):1130-8. PubMed ID: 25963952
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood.
Zhang Z; Zhao X; Zhang T; Wang L; Yang L; Huang L; Li F; Liu J; Yue D; Wang F; Li J; Guan F; Xu Y; Zhang B; Zhang Y
Cytotherapy; 2015 Jan; 17(1):86-97. PubMed ID: 25457278
[TBL] [Abstract][Full Text] [Related]
11. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers.
Todorovic M; Mesiano G; Gammaitoni L; Leuci V; Giraudo Diego L; Cammarata C; Jordaney N; Carnevale-Schianca F; Gallo S; Fagioli F; Piacibello W; Elia AR; Pignochino Y; Dell'aglio C; Grignani G; Cignetti A; Aglietta M; Sangiolo D
J Immunother; 2012 Sep; 35(7):579-86. PubMed ID: 22892454
[TBL] [Abstract][Full Text] [Related]
13. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
[TBL] [Abstract][Full Text] [Related]
14. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies.
Niu Q; Wang W; Li Y; Qin S; Wang Y; Wan G; Guan J; Zhu W
Int Immunopharmacol; 2011 Apr; 11(4):449-56. PubMed ID: 21215350
[TBL] [Abstract][Full Text] [Related]
15. Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use.
Gotti E; Tettamanti S; Zaninelli S; Cuofano C; Cattaneo I; Rotiroti MC; Cribioli S; Alzani R; Rambaldi A; Introna M; Golay J
Cytotherapy; 2022 Mar; 24(3):334-343. PubMed ID: 35063359
[TBL] [Abstract][Full Text] [Related]
16. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cytotoxic potency between freshly cultured and freshly thawed cytokine-induced killer cells from human umbilical cord blood.
Ngo HT; Dang VT; Nguyen NH; Bui AN; Van Pham P
Cell Tissue Bank; 2023 Mar; 24(1):139-152. PubMed ID: 35792988
[TBL] [Abstract][Full Text] [Related]
18. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
[TBL] [Abstract][Full Text] [Related]
19. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.
Shah N; Martin-Antonio B; Yang H; Ku S; Lee DA; Cooper LJ; Decker WK; Li S; Robinson SN; Sekine T; Parmar S; Gribben J; Wang M; Rezvani K; Yvon E; Najjar A; Burks J; Kaur I; Champlin RE; Bollard CM; Shpall EJ
PLoS One; 2013; 8(10):e76781. PubMed ID: 24204673
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]